In another study that evaluated the efficacy and safety of CD30 CAR T-cell therapy, nine patients with R/R CD30+ lymphoma, including six HL and three ALCL were enrolled from September 2016 to November 2018. This evidence concerns the gene TNFRSF8 and lymphoma.